News
August 1, 2019
EIP Pharma to Present at Canaccord Genuity 39th Annual Growth Conference
EIP Pharma, Inc., a CNS-focused therapeutics company, today announced that company management will present at the Canaccord Genuity 39th Annual Growth Conference on Thursday, August 8, 2019, at 12:00 p.m. ET in Boston, MA.
Read MoreJuly 17, 2019
EIP Pharma Announces Presentation of Preclinical Data Demonstrating Effects of p38α Kinase Inhibitor Neflamapimod on the Neurodegenerative Process
Presentations at Late Breaker Session at Alzheimer’s Association International Conference (AAIC) 2019 Cambridge, Mass., July 17, 2019 – EIP Pharma, Inc., a CNS-focused therapeutics company, today announced that new preclinical data regarding neflamapimod were presented at the AAIC 2019 scientific meeting in Los Angeles, CA (July 14-18, 2019). “The findings add to the growing body […]
Read MoreJuly 12, 2019
EIP Pharma Initiates New Study with Neflamapimod for the Treatment of Cognitive Deficits in Patients with Dementia with Lewy Bodies
The primary objective of the study is to determine whether neflamapimod, a brain-penetrant, oral small molecule that inhibits the enzyme p38 alpha, can reverse the hippocampal synaptic dysfunction associated with DLB.
Read MoreView All News
Presentations
June 21, 2019
EIP KOL breakfast briefing on potential of neflamapimod in Alzheimer’s disease and dementia with Lewy bodies (June 21, 2019 8:00 AM EST)
Read More
June 20, 2019
Presentation at JMP Securities Life Sciences Conference (June 20, 2019 1:00 PM EST)
Read More
June 7, 2019
Corporate presentation at Jefferies 2019 Healthcare Conference on June 7, 2019
Read More
View All Presentations
About EIP
Are you a patient, caregiver, clinician or professional and want to learn more about EIP Pharma’s approach? Please contact us.
Contact Us